Glycoconjugates tune the viscoelastic signature of mammary tumor progression
- 1University of California, Santa Barbara
Abstract
Breast cancer progression involves extensive remodeling of the tumor extracellular matrix (ECM), resulting in changes in mechanical properties. Tumors are viscoelastic, exhibiting both an initial elastic response to loading and a time-dependent viscous response. While it is well established that tumor elasticity or stiffness is elevated, changes in tissue viscoelasticity during breast cancer progression remain poorly characterized. Here, using a mouse model that recapitulates stages of human breast cancer progression (mouse mammary tumor virus-polyoma middle T antigen, MMTV-PyMT), we show that tumors from both early and late disease time points were significantly more viscoelastic than normal mammary glands. Spatial microindentation revealed that while local stiffness and viscoelasticity are strongly coupled in soft regions of normal tissue, this relationship weakens in late carcinoma. Compared to normal glands, carcinoma tissues also exhibited marked upregulation of glycosaminoglycans (GAGs) and glycoproteins. Selective enzymatic degradation of sulfated GAGs, mucins, or O/N-linked glycans reduced viscoelasticity without altering stiffness, establishing glycoconjugates as major contributors to tumor viscoelasticity. In vitro, increasing matrix viscoelasticity drove non-transformed mammary epithelial cells (MCF10A) toward a malignant phenotype through focal adhesion kinase mechanosignaling. Our work establishes increased viscoelasticity as a defining mechanical feature of breast cancer progression, driven in part by the accumulation of glycoconjugates. These findings provide a fuller picture of tumor mechanical evolution and a benchmark for recapitulating matrix viscoelasticity in engineered models of breast cancer.
Related
- Primary tumor transcriptomic signature is associated with locoregional dissemination in canine mammary carcinoma
- Targeting cGMP pathways: the impact of vericiguat and high intensity interval training on mammary cancer progression in female mice
- Systemic Metastatic Progression of Canine Mammary Comedocarcinoma with Pathological Femoral Fracture: A Case Report.
- When Mammary-Like Anogenital Glands Go Rogue: Vulvar Phyllodes Tumor With Incorporated Hidradenoma Papilliferum.
- Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
BibTeX
@misc{sharma2026glycoconjugates,
title = {{Glycoconjugates tune the viscoelastic signature of mammary tumor progression}},
author = {A. Sharma and J. A. Baude and M. Papez and M. Gionet-Gonzales and R. S. Stowers},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.20.760544},
url = {https://www.biorxiv.org/content/10.64898/2026.10.20.760544v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Glycoconjugates tune the viscoelastic signature of mammary tumor progression
AU - A. Sharma
AU - J. A. Baude
AU - M. Papez
AU - M. Gionet-Gonzales
AU - R. S. Stowers
PY - 2026
DA - 2026/10/20
PB - bioRxiv
DO - 10.64898/2026.10.20.760544
UR - https://www.biorxiv.org/content/10.64898/2026.10.20.760544v1
AB - Breast cancer progression involves extensive remodeling of the tumor extracellular matrix (ECM), resulting in changes in mechanical properties. Tumors are viscoelastic, exhibiting both an initial elastic response to loading and a time-dependent viscous response. While it is well established that tumor elasticity or stiffness is elevated, changes in tissue viscoelasticity during breast cancer progression remain poorly characterized. Here, using a mouse model that recapitulates stages of human breast cancer progression (mouse mammary tumor virus-polyoma middle T antigen, MMTV-PyMT), we show that tumors from both early and late disease time points were significantly more viscoelastic than normal mammary glands. Spatial microindentation revealed that while local stiffness and viscoelasticity are strongly coupled in soft regions of normal tissue, this relationship weakens in late carcinoma. Compared to normal glands, carcinoma tissues also exhibited marked upregulation of glycosaminoglycans (GAGs) and glycoproteins. Selective enzymatic degradation of sulfated GAGs, mucins, or O/N-linked glycans reduced viscoelasticity without altering stiffness, establishing glycoconjugates as major contributors to tumor viscoelasticity. In vitro, increasing matrix viscoelasticity drove non-transformed mammary epithelial cells (MCF10A) toward a malignant phenotype through focal adhesion kinase mechanosignaling. Our work establishes increased viscoelasticity as a defining mechanical feature of breast cancer progression, driven in part by the accumulation of glycoconjugates. These findings provide a fuller picture of tumor mechanical evolution and a benchmark for recapitulating matrix viscoelasticity in engineered models of breast cancer.
ER -